A secondary analysis of TRAILBLAZER-ALZ 2 strengthens the case that reducing amyloid plaques underlies the clinical benefits ...

A new study has identified a mutation in the TREM2 gene that disrupts the brain’s ability to clear toxic amyloid plaques, increasing Alzheimer’s disease risk.

In a study published in Neuron, a research team at the Department of Neurology at Massachusetts General Hospital, aimed to ...

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function. - ...

A new study provides a well-needed glimmer of hope for treating Alzheimer’s disease. Focusing on a genetic form of early-onset dementia called dominantly inherited Alzheimer’s disease, scientists have ...

Spanish and Chinese scientists say they have used nanoparticles to enable the brains of mice to clear out plaque linked to ...

As resident trash collectors, microglia survey the brain in search of detritus for disposal. How do they recognize the debris? In the case of plaques, a cell-surface receptor might be involved, though ...

Discover how donanemab’s impact on posttreatment amyloid levels may transform Alzheimer’s treatment. Keep reading to learn ...

Clumps or plaques of the protein beta-amyloid in the brain are a hallmark of a type of dementia called Alzheimer’s disease. When beta-amyloid plaques form, they disrupt communication between nerve ...

Kisunla will be the more expensive per-year option, with a list price of $32,000, compared to Leqembi, which is priced at $26,500 per year. With Biogen and Eisai expanding the U.S. Leqembi sales team, ...